The stock of Capricor Therapeutics, Inc. (NASDAQ:CAPR) is now priced at $6.03 and the shares are 0.77 points up or 14.64% higher compared to its previous closing price of $5.26. The stock had 1.933 million contracts set over the past session. CAPR shares’ daily volume is compared to its average trading volume at 2.642 million shares. However, it has a float of 19.22 million and although its performance was 9.44% over the week, it’s one to watch. It means the stock’s downside potential is -100% with the CAPR share price recently placing at $5.14 to $6.26. However, some brokerage firms have priced the stock below the average, including one that has called $12.

The shorts are climbing into the Capricor Therapeutics, Inc. stock, with the latest data on short interest released on August 14, 2020, showing that short interest numbers in the CAPR shares have risen. Short interest in the stock represents just 10.73% of its float, but the volume has raised by 877544. The volume of shorted shares rised to 2.063 million from 1.185 million shares over the last two weeks. The average intraday trading volume has been 3.388 million shares, which means that days to cover moved to roughly 1.

In the last trading session, Capricor Therapeutics, Inc. (NASDAQ:CAPR) raised by $0.52 over the week and lost -$1.65 on its 20-day. The stock’s high in the recent session is lower when compared to its 52-week high of $12.32. The stock recorded its established 52-week high on 07/28/20.

Since 03/12/20, the stock has traded to a low of $0.88 at 585.23%, an encouraging piece of data likely to interest most investors out to exploit the stock’s recent surge. The stock has a beta allocation of 6.92. Being above 1 means that the stock’s volatility is higher than the market and traders are keenly watching it.

Looking at current readings, Capricor Therapeutics, Inc.’s two-week RSI is 49.49. This suggests that the stock is neutral at the moment and that CAPR shares’ price movement remains stable. The stochastic readings are equally revealing at 29.12% meaning the CAPR share price is currently in overbought territory.

The technical chart shows that the CAPR stock will likely settle at between $6.48 and $6.93 per share. However, if the stock dips below $5.36, then its market would become much weaker. Any downside could see the stock price sliding to levels as low as $4.69.

Currently, the stock is trading in the red of MACD, with a reading of -0.24. Investors always pay attention to any move above or below the zero-line, mainly because the indicator points to the position of the stock’s short-term average relative to its long-term measure. A MACD -a reading above the zero line means that the short-term is above the long-term average. This scenario implies that there is an upward momentum. The opposite is true when the MACD falls below the zero-line.

Analysts at Maxim Group cut their recommendation for CAPR from Buy to Hold in December 26 review. H.C. Wainwright analysts see the stock as a Buy, but they also raised the share’s target price from $6.50 to $8.60 in a flash note released to investors on January 26. H.C. Wainwright analysts see the stock as Buy. Nonetheless, the analysts revised the share prices up on September 15, placing it at $6.50 from $2.15.

The average rating for the CAPR equity is 2 and is currently gathering a bullish momentum. Of 2 analysts tracking Capricor Therapeutics, Inc. polled by Reuters, 0 rated CAPR as a hold. The remaining 2 analysts were split evenly. However, the split wasn’t equal as a majority (2) rated it as a buy or strong buy. 0 analyst advised investors against buying the stock or to sell if they own any of the stock.

Zacks Consensus Estimate forecasts that the current-quarter revenues for Capricor Therapeutics, Inc. (NASDAQ:CAPR) will increase by about 320.84%, which will see them reach $210 million. The company’s full-year revenues are, however, expected to increase by about 56900%, up from $1 million to $570 million. CAPR’s expected adjusted earnings should drop almost -13.95% to end up at -$0.37 per share, while for the fiscal year, analysts project the company’s earnings to drop by about -29.13% to record -$1.46/share.